CA Patent

CA2855368A1 — Biomarkers of response to proteasome inhibitors

Assigned to Millennium Pharmaceuticals Inc · Expires 2013-05-16 · 13y expired

What this patent protects

Disclosed herein are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are provided to assess markers of marker genes to predict outcome with proteasome inhibiti…

USPTO Abstract

Disclosed herein are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are provided to assess markers of marker genes to predict outcome with proteasome inhibition treatment

Drugs covered by this patent

Patent Metadata

Patent number
CA2855368A1
Jurisdiction
CA
Classification
—
Expires
2013-05-16
Drug substance claim
No
Drug product claim
No
Assignee
Millennium Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.